Imperial College-London: First-in-class Drug Candidate for Multiple Myeloma Shows Promise in Phase 1 Trial
February 23, 2026
February 23, 2026
LONDON, England, Feb. 23 -- Imperial College-London issued the following news:
* * *
First-in-class drug candidate for multiple myeloma shows promise in Phase 1 trial
By David Silverman
A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.
Multiple myeloma (MM) is a cancer of plasma cells, accounting for . . .
* * *
First-in-class drug candidate for multiple myeloma shows promise in Phase 1 trial
By David Silverman
A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.
Multiple myeloma (MM) is a cancer of plasma cells, accounting for . . .